Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T00663 Target Info
Target Name Stress-activated protein kinase JNK3 (JNK3)
Synonyms Stress-activated protein kinase 1b; SAPK1b; PRKM10; Mitogen-activated protein kinase 10; MAPK 10; MAP kinase p49 3F12; MAP kinase 10; JNK3A; C-Jun N-terminal kinase 3
Target Type Patented-recorded Target
Gene Name MAPK10
Biochemical Class Kinase
UniProt ID
MK10_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2013074986
Title Inhibitors of C-Jun-N-Terminal Kinase (Jnk).
Abstract The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L1, L2, RA, RC, RD, RE, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases.
Applicant(s) Dana-Farber Cancer Institute, Inc
Representative Drug(s) D0ZU8L Drug Info IC50 = 0.5 nM Click to Show More [1]
2 D08JOC Drug Info IC50 = 0.8 nM [1]
3 D0RQ8Q Drug Info IC50 = 1 nM [1]
Patent ID WO2010091310
Title Inhibitors of Jun N-Terminal Kinase.
Abstract The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
Applicant(s) Elan Pharmaceuticals, Inc
Representative Drug(s) D0X2SG Drug Info IC50 = 6 nM Click to Show More [1]
2 D0W8BL Drug Info IC50 = 9 nM [1]
3 D08DNZ Drug Info IC50 = 11 nM [1]
4 D0L2MS Drug Info IC50 = 2200 nM [1]
Patent ID WO2010015803
Title Diazaindole Derivatives and Their Use In The Inhibition of C-Jun N-Terminal Kinase.
Abstract The invention relates to diazaindole derivatives represented by the general formula (I): where A, E, G, R1, R2, R3 and R4 are defined herein, or pharmaceutically acceptable salts thereof, their use in the inhibition of c-Jun N-terminal kinase (JNK) activity, their use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases, autoimmune diseases and/or organ failure. The invention also provides processes for the manufacture of said diazaindole derivatives and compositions containing them.
Applicant(s) Eisai R & D Management Co. Ltd
Representative Drug(s) D05SJB Drug Info IC50 = 32 nM Click to Show More [1]
2 D07KMK Drug Info IC50 = 40 nM [1]
3 D0VR1O Drug Info IC50 = 85 nM [1]
4 D0T6IZ Drug Info IC50 = 129 nM [1]
5 D04BIF Drug Info IC50 = 178 nM [1]
6 D0U9RB Drug Info IC50 = 1700 nM [1]
7 D0JB7I Drug Info IC50 > 2000 nM [1]
Patent ID WO2008095944
Title 7-Azaindole Derivatives and Their Use In The Inhibition of C-Jun N-Terminal Kinase.
Abstract The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.
Applicant(s) Eisai R & D Management Co. Ltd
Representative Drug(s) D05SJB Drug Info IC50 = 32 nM Click to Show More [1]
2 D07KMK Drug Info IC50 = 40 nM [1]
3 D0VR1O Drug Info IC50 = 85 nM [1]
4 D0T6IZ Drug Info IC50 = 129 nM [1]
5 D04BIF Drug Info IC50 = 178 nM [1]
6 D0U9RB Drug Info IC50 = 1700 nM [1]
7 D0JB7I Drug Info IC50 > 2000 nM [1]
Patent ID WO2013091670
Title Novel Jnk Inhibitor Molecules for Treatment of Various Diseases.
Abstract The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.
Applicant(s) COMBETTE, Jean-Marc et al
Representative Drug(s) D0Q4WA Drug Info IC50 = 103 nM [1]
Patent ID WO2011071491
Title Isotopologues of 4-[9-(Tetrahydro-Furan-3-Yl)-8-(2, 4, 6- Trifluoro-Phenylamino)-9H-Purin-2-Ylamino]-Cyclohexan-1-Ol.
Abstract Provided herein are isotopologues of Compound 1, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.
Applicant(s) Signal Pharmaceuticals
Representative Drug(s) D06JRV Drug Info IC50 = 6 nM [1]
Patent ID WO2010069833
Title Pyrimidin- 2 -Ylamino Derivatives and Their Use To Treat Inflammation.
Abstract Compounds of formula (I) modulate JNK wherein X1 and X2 are each simultaneously N or CH; X3 is CH-R2 or N-SO2R, where R is lower alkyl; R1 is aryl or heteroaryl, substituted with 0-3 lower alkyl radicals; R2 is formula (II), where R3 is H, lower acyl, or an amino acid, or a pharmaceutically acceptable salt thereof.
Applicant(s) F. Hoffmann-La Roche Ag
Representative Drug(s) D0H4HD Drug Info IC50 = 114 nM [1]
Patent ID WO2008028860
Title Benzotriazole Kinase Modulators.
Abstract The invention is concerned with novel benzotriazole derivatives of Formula (I) Wherein R, R1, R2, R3, and m are as defined in the description and the claims, as well as physiologically acceptable salts thereof. These compounds are JNK and CDK modulators.
Applicant(s) F. Hoffmann-La Roche Ag
Representative Drug(s) D0H4HD Drug Info IC50 = 114 nM [1]
References  Top
REF 1 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.